8-K: Progyny Reports Strong Q3 2025, Raises Full-Year Guidance

Progyny, Inc. announced robust third-quarter 2025 financial results, including 9.3% revenue growth and a raised full-year outlook, driven by strong member engagement and successful client acquisition.

Summary

• Revenue for Q3 2025 was $313.3 million, a 9.3% increase compared to Q3 2024, or 23% growth when excluding the impact of a large former client.
• Gross profit increased by 23% to $72.8 million in Q3 2025, with gross margin expanding to 23.2% from 20.7% in the prior year period.
• Net income for Q3 2025 was $13.9 million, or $0.15 per diluted share, up from $10.4 million, or $0.11 per diluted share, in Q3 2024.
• Adjusted EBITDA grew by 18% to $55.0 million in Q3 2025, with Adjusted EBITDA margin reaching 17.5% compared to 16.2% in Q3 2024.
• The company generated a record $156.0 million in operating cash flow over the first nine months of 2025.
• The latest selling season yielded over 80 new clients, representing approximately 900,000 new covered lives, and achieved a near 100% retention rate of existing clients for 2026.
• New programs, including pregnancy-postpartum, menopause, and leave and benefit navigation, will be accessible to over 2.7 million lives next year, an incremental 1.2 million lives above 2025.
• The Board of Directors authorized a new share repurchase program of up to $200 million.
• Full-year 2025 revenue guidance was raised to a range of $1.263 billion to $1.278 billion, reflecting 8.2% to 9.5% growth.
• Full-year 2025 Adjusted EBITDA guidance was raised to a range of $216.0 million to $220.0 million.
• As of September 30, 2025, the company had 553 fertility and family building clients, up from 468 clients in Q3 2024.
• The company anticipates having over 600 clients, representing approximately 7.6 million covered lives, once all new clients from the recent selling season are live in 2026.

Sentiment

Score: 8

Explanation: The company reported strong financial results, including significant revenue and profit growth, and raised its full-year guidance. Successful client acquisition, high retention rates, and the authorization of a share repurchase program indicate robust operational health and a positive outlook, despite the non-renewal of a large client.

Positives

• Strong Q3 2025 revenue growth of 9.3% ($313.3 million), or 23% when excluding the impact of a large, former client.
• Significant increase in gross profit (23% to $72.8 million) and gross margin expansion (23.2% from 20.7%).
• Adjusted EBITDA increased by 18% to $55.0 million, with margin expansion to 17.5%.
• Record $156.0 million in operating cash flow generated over the first nine months of 2025.
• Successful selling season secured over 80 new clients and approximately 900,000 new covered lives for 2026.
• Achieved near 100% retention of existing clients for 2026, with nearly 30% of existing clients expanding benefits.
• New programs (pregnancy-postpartum, menopause, leave/benefit navigation) are resonating, adding 1.2 million incremental lives for 2026, totaling 2.7 million lives.
• Raised full-year 2025 guidance for revenue, net income, Adjusted EBITDA, and Adjusted earnings per diluted share.
• Board authorized a new share repurchase program of up to $200 million, indicating financial strength and commitment to shareholder value.
• Strong balance sheet with $345.2 million in cash and marketable securities and no debt.
• Improved Days Sales Outstanding (DSO) to 72.5 days as of September 2025, an improvement of more than 15 days from the year-ago period.

Negatives

• A large client did not renew its services agreement for 2025, though an extended transition period mitigated some impact in the first half of 2025.
• Interest and other income, net, was lower in Q3 2025 ($2.437 million) compared to Q3 2024 ($5.504 million).
• Female utilization rate for YTD 2025 slightly decreased to 0.88% from 0.90% in the prior year.

Risks

• Failure to meet publicly announced guidance or other expectations about the business.
• Competition in the market in which the company operates.
• History of operating losses and ability to sustain profitability.
• Unfavorable conditions in the industry or the United States economy.
• Limited operating history and difficulty in predicting future results of operations.
• Ability to attract and retain clients and increase the adoption of services within the client base.
• The loss of any of the largest client accounts.
• Changes in the technology industry or developments in the health insurance market.
• Negative publicity in the health benefits industry.
• Lags, failures, or security breaches in computer systems or those of vendors.
• A significant change in the utilization of solutions.
• Ability to offer high-quality support and obtain positive references from existing clients.
• Ability to develop and expand marketing and sales capabilities.
• The rate of growth of future revenue.
• Accuracy of the estimates and assumptions used to determine the size of target markets.
• Ability to successfully manage growth.
• Reductions in employee benefits spending.
• Seasonal fluctuations in sales.
• The adoption of new solutions and services by clients or members.
• Ability to innovate and develop new offerings.
• Ability to adapt and respond to the changing medical landscape, regulations, and client needs, requirements or preferences.
• Ability to maintain and enhance the brand.
• Ability to attract and retain members of the management team, key employees, or other qualified personnel.
• Risks related to any litigation against the company.
• Ability to maintain the Center of Excellence network of healthcare providers.
• Strategic relationships with and monitoring of third parties.
• Ability to maintain the pharmacy distribution network if there is a disruption to the network or its associated supply chains.
• Relationship with key pharmacy program partners or any decline in rebates provided by them.
• Ability to maintain relationships with benefits consultants.
• Exposure to credit risk from members.
• Risks related to government regulation and business with government entities.
• Ability to protect intellectual property rights.
• Risks related to acquisitions, strategic investments, or partnerships.
• Federal tax reform and changes to the effective tax rate.
• The imposition of state and local state taxes.
• Ability to utilize a portion of net operating loss or research tax credit carryforwards.
• Ability to develop or maintain effective internal control over financial reporting.
• Ability to adapt and respond to the changing SEC or stakeholder expectations regarding environmental, social and governance practices.

Future Outlook

The company raised its full-year 2025 guidance for revenue, net income, Adjusted EBITDA, and Adjusted earnings per diluted share, reflecting strong member engagement and successful client acquisition. They anticipate having over 600 clients and approximately 7.6 million covered lives in 2026, with new clients primarily going live in Q1 2026. Guidance for 2026 will be provided with year-end results in February. The outlook considers potential macroeconomic uncertainty and investments in member experience and acquisition integration.

Management Comments

• "Our strong results this quarter reflect that members have continued to pursue the care and services they need in order to best address both their family building goals and their overall health, and did so at levels that exceeded our expectations." Pete Anevski, CEO.
• "We're equally pleased with the results of our latest selling season, which resulted in commitments from over 80 new clients representing approximately 900,000 new lives, as well as a near 100% client retention rate for 2026, in addition to strong expansions of services across existing accounts." Pete Anevski, CEO.
• "Our newest programs including pregnancy-postpartum, menopause, and leave and benefit navigation continue to resonate in the market, further demonstrating both the underlying need for these services, as well as the measurable value that our solutions deliver." Pete Anevski, CEO.
• "More than 2.7 million lives will have access to one or more of those solutions next year, or an incremental 1.2 million lives above 2025." Pete Anevski, CEO.
• "The third quarter results reflect both strong revenue growth and margin expansion, and through our continuing focus on prudent management of our business operations, we've maintained a high conversion of Adjusted EBITDA to cash flow, yielding a record $156 million in operating cash flow over the first nine months of the year." Mark Livingston, CFO.
• "Given our balance sheet strength and solid cash position, we're pleased to be in a position to return value to our shareholders through our latest share repurchase program, which we'll pursue while also maintaining the ability to continue investing in our business for future growth." Mark Livingston, CFO.
• "In light of our strong results over the first nine months of the year, as well as our expectations for member engagement over the remainder of the year, we're pleased to raise our full year guidance." Pete Anevski, CEO.

Industry Context

Progyny operates in the growing women's health and family building solutions market. The strong client acquisition and expansion into new programs like pregnancy-postpartum and menopause indicate a broader industry trend towards comprehensive, employer-sponsored health benefits that address a wider range of employee needs beyond traditional fertility. The continued demand for these services, despite macroeconomic uncertainty, suggests the essential nature and perceived value of Progyny's offerings in the competitive benefits landscape.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to global benchmarks for direct comparison.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, raised guidance, and a new $200 million share repurchase program, indicating potential for increased shareholder value.
• Employees: Continued growth and expansion into new programs suggest job stability and potential for growth opportunities.
• Customers (Clients): High client retention (near 100%) and expansion of services indicate satisfaction and continued value from Progyny's solutions.
• Members: Increased access to new programs (pregnancy-postpartum, menopause, leave/benefit navigation) and continued strong member engagement suggest improved health and family building outcomes.

Next Steps

• New clients from the latest selling season are expected to go live primarily in Q1 2026.
• The company anticipates providing financial guidance for 2026 when it reports its year-end results in February.
• The company plans to pursue the $200 million share repurchase program.
• Continue investing in the business for future growth.

Key Dates

Recommendation

The company delivered strong Q3 2025 results, exceeding expectations with significant revenue growth (especially excluding the former large client), margin expansion, and record operating cash flow. The successful selling season, near 100% client retention, and expansion into new women's health programs demonstrate robust business fundamentals and strong market demand. The raised full-year guidance and the authorization of a $200 million share repurchase program further underscore management's confidence and commitment to shareholder value. The strong balance sheet with no debt provides significant financial flexibility for future investments and shareholder returns. These factors collectively point to a very positive outlook for the company.

Keywords

Progyny, PGNY, financial results, Q3 2025, earnings, revenue growth, Adjusted EBITDA, operating cash flow, share repurchase, fertility benefits, family building solutions, women's health, client acquisition, guidance, healthcare benefits, corporate governance